Comparacion de estrategias terapeuticas para el control de la tension arterial y la angina de pecho en pacientes con hipertension arterial y cardiopatia isquemica cronica
Autor: Dr. Jose Raul Nodarse Valdivia | Publicado:  13/04/2007 | Cardiologia | |
Comparacion de estrategias terapeuticas para el control de la tension arterial y la angina de pecho


28.- Savanitto S, Ardissino D, Egstrup K, Rasmusen K, Bae EA, Om Lord T, et al.Combination Therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) study. J Am Coll Cardiol;27: 311-6.
29.- The Tibet Study Group. The Total Ischaemic Burden European Trial ( TIBET) : design, methodology and management. Cardiovasc Drugs Ther 1992; 6: 379 –86.
30.- Von Armin T. Medical Treatment to reduce total ischemic burden : Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J AM Coll Cardiol. 1995; 25: 231-8.
31.- Rehnquist N, Hjemdahl P, Billing E, Bjarkkarder I, Erihsson SV, Forslund L, et al. Effects of metoprolol versus verapamil in patients with stable angina pectoris (APSIS). European Heart J 1996; 17: 76-81.
32.- ASCOT investigators. Rationale, design, methods and baseline demography of participants of The Anglo Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19:1139-47.
33.- PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis on the occurrence of clinical events. Circulation 2000; 102: 1503-10.
34.- Groning E, García Barreto D. Antagonistas del calcio. Rev Cubana Cardiol Circ Cardiovasc 1989; 4: 103-9.
35.- García Barreto D. Los antagonistas del calcio en el tratamiento de la isquemia miocárdica III. Rev Cubana Cardiol Circ Cardiovasc 1990; 4: 94-106.
36.- García Barreto D, Toruncha AC. Los inhibidores de la enzima conversora de angiotensina. Rev Cubana Cardiol Circ Cardiovasc 1997; 11: 29-46.
37.- TRACE Study Group. Effects of ACE-inhibitor on life expentacy of patients with reduced left-ventricular function after myocardial infarction. Lancet 1999; 354: 9-12.
38.- Hernández Castro A, Gonzáles A, Cardonne A, Peréz Medina T, García Barreto D. Effects of atenolol in angina pectoris of effort. Cor Vasa 1978; 20 99-103.
39.- Wilhelmsen L, Berglund G, Elmfeldt, et al. Beta-blochers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J Hypertens 1987; 5; 561-72.
40.- Amery A, Berkenhogen WH, Bulpett CJ, Dollery CT. The European Working Party on High blood pressure in the Elderly. Am J Med 1991; 90:3A-1S-64S.
41.- The MRFIT research group. Multiple Risk Factor Intervention Trial. JAMA1982; 248:1465-77.
42.- Erdine S, Handberg E, Kolb B. Characteristics of patients with Coronary Artery Disease and Hypertension: A Report from INVEST. Clin. Cardiol. 2001; 24: v-6-v-8.
43.- Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birbenhoger WH, Bulpitt CJ. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
44.- Pepine C. The European INVESTigators Meeting. Clin. Cardiol. 2001; 24: A6.
45.- Wallis E, Ramsay L, Jackson P. Cardiovascular and coronary risk estimation in hypertension management. Heart 2002; 88: 306-312.
46.- Kannel WB, Cupples La, D’Agostino RB, Stokes J. Hypertension, antihypertensive treatment and sudden coronary death. The Framingham Study. Hypertension 1998; 11: 1145-50.
47.- Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high normal blood pressure. Arch Intern Med 1997; 157: 657-667
48.- Stamler R, Stamler J, Gash F, et al. Primary prevention of hypertension by nutritional hygienic means. JAMA 1989; 262: 1801-1807.
49.- Schneider M, Lerch M, Papiri M, Buechel P, Boehlen L, Shaw S, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to betablocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1996; 14(5):669-77.
50.- Goodman and Gilmans. The Pharmacological Basis of therapeutics. Mc Graw-Hill. Philadelphia, 1998: 723-37.
51.- Hulley S, Ashman P, Kuller L, Lasser N, Sherwin R. HDL-cholesterol levels in the Multiple Risk Factor Intervention Trial (MRFIT). Lipids 1979;14:119-123.
52.- Escobar Blanco A. Factores de riesgo coronario en personas adultas de un área de salud de Rancho Veloz. Villa Clara 2005. [Trabajo de Terminación de Especialidad]. Policlínico Docente “Mártires del 10 de Abril. ISCM – Villa Clara, 2005.
53.- ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1998; 2 (8607): 349-60.
54.- Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105 (5): 557-63.
55.- Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).Circulation 2002; 105: 2962-7.

Autores:

Dr. Jose Raúl Nodarse Valdivia
Dr. Arnaldo Rodríguez León
Dr. Francisco Luis Moreno-Martínez
Dr. José Ignacio Ramírez Gómez
Dra. Yaifa Márquez Espino
Dra. Omaida J. López Bernal

CARDIOCENTRO “ERNESTO CHE GUEVARA” . SANTA CLARA, CUBA



Revista Electronica de PortalesMedicos.com
INICIO - NOVEDADES - ÚLTIMO NÚMERO - ESPECIALIDADES - INFORMACIÓN AUTORES
© PortalesMedicos, S.L.
PortadaAcerca deAviso LegalPolítica de PrivacidadCookiesPublicidadContactar